MRNS – marinus pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
11/18
03:07 am
mrns
Low
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/15
06:15 am
mrns
Medium
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results [Yahoo! Finance]
11/14
10:12 am
mrns
Medium
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
11/14
08:15 am
mrns
Low
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
11/12
07:04 pm
mrns
High
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/12/2024
04:00 pm
mrns
-12.4%
BEAT
8/13/2024
07:00 am
mrns
-4.1%
MISS
5/8/2024
07:00 am
mrns
-9.5%
IN-LINE
3/5/2024
04:01 pm
mrns
-2.3%
MISS
11/14
10:12 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Medium
4.6%
11/14
09:28 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
-1.2%
11/14
08:15 am
Reiterates
Neutral
Neutral
HC Wainwright
Low
-1.3%
10/25
04:22 pm
Reiterates
Buy
Neutral
HC Wainwright
Medium
-6.6%
10/25
01:25 pm
Maintains
Sector Perform
Sector Perform
RBC Capital
High
21.4%
11/15
10:35 am
mrns
Low
Form SC 13G/A MARINUS PHARMACEUTICALS, Filed by: PRUDENTIAL FINANCIAL INC
11/15
08:00 am
mrns
Low
Form 8-K MARINUS PHARMACEUTICALS, For: Nov 14
11/14
06:39 pm
mrns
Medium
Form SC 13G MARINUS PHARMACEUTICALS, Filed by: Sofinnova Investments, Inc.
11/14
03:05 pm
mrns
Low
Form SC 13G/A MARINUS PHARMACEUTICALS, Filed by: Cormorant Asset Management, LP
11/14
12:24 pm
mrns
Low
Form SC 13G/A MARINUS PHARMACEUTICALS, Filed by: EVENTIDE ASSET MANAGEMENT, LLC
Show more
Top News Gainers
12/10 Form 424B5 MARINUS PHARMACEUTICALS 52.1%
12/19 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 37.3%
3/19 Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications 37.3%
3/20 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 36.4%
7/25 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $3.00 price target on the stock. 24.4%
3/16 Form 10-K MARINUS PHARMACEUTICALS For: Dec 31 21.0%
2/14 Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 16.4%
2/24 Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences 16.3%
3/23 MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) 12.9%
9/26 Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial 12.7%
Top News Decliners
7/23 Form 8-K MARINUS PHARMACEUTICALS For: Jul 23 -21.6%
3/16 Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results -20.7%
4/1 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -13.1%
9/26 Marinus up 58% premarket on positive ganaloxone data [Seeking Alpha] -11.5%
9/26 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -10.1%
10/17 Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting -7.6%
11/18 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -7.6%
10/29 Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer -7.5%
4/2 Form 8-K MARINUS PHARMACEUTICALS For: Mar 31 -7.5%
12/12 Form 424B5 MARINUS PHARMACEUTICALS -6.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3